Description
BenevolentAI was known for applying artificial intelligence to drug discovery in biopharma. Its site now centers on a different product, Qor, described as "an always-on strategic function for biopharma decision makers and life science consultancies" rather than a research or discovery tool. BenevolentAI is registered in Luxembourg.
Read More
Qor is built on BenevolentAI's existing knowledge graph and scientific ontologies, developed over more than a decade of applying AI to biomedical evidence. Rather than generating new discovery leads, Qor continuously re-checks a company's existing positions, on a drug's competitive landscape, on how a rival's trial result affects an asset, or on whether a previous analysis still holds, and tells the user when the underlying facts have changed. BenevolentAI contrasts this with data subscriptions, generic large language models or manual analyst work, arguing each leaves gaps that Qor is built to close.
Qor runs every factual claim through what BenevolentAI calls a source-verification pass before presenting it, and applies the same analytical workflow to every update so users can see what changed and why. It works across multiple functions at once, clinical design, business development, investor narrative, IP and cash runway, and is meant to keep a client's strategic position current as new evidence emerges, rather than producing a one-time report.
Customers quoted on the Qor site include a head of cell therapy at a biotech, a chief executive of a single-asset biotech spinout, a director of discovery at a metabolic-disease biotech, and partners at life-science strategy and pricing consultancies; BenevolentAI positions Qor for both in-house biopharma teams and outside consultants advising them.
BenevolentAI's public site currently gives few specifics on Qor's pricing or deployment model beyond a book-a-demo call to action, and does not describe ongoing drug-discovery research programs of its own the way its earlier positioning did. Its most recent published investor report on the site dates to 2024, so its current corporate and financial status cannot be confirmed from the site alone.
- CategoryScientific Discovery & Lab Tools
- Pricing ModelContact sales
- DeploymentCloud
- PlatformsWeb
BenevolentAI's Core Features
Continuous evidence tracking that flags when a previously accepted scientific or market conclusion changes.
Source-verification pass applied to every factual claim before it reaches the user.
Consistent analytical workflow re-run on every update, so users can see what changed and why.
Coverage across clinical design, business development, investor narrative, IP and cash runway in one view.
Built on BenevolentAI's existing knowledge graph and life-sciences ontologies.
Positioning analysis that benchmarks an asset or indication against the wider competitive field.
Board-ready outputs meant to replace long manual research reports.
How to use BenevolentAI?
Book a demo: Contact BenevolentAI to see Qor applied to your asset or indication.
Define your focus: Set the drug, indication or market you want Qor to track.
Get an initial position: Qor surfaces the current competitive and evidentiary picture.
Monitor for changes: Qor continuously re-checks the evidence and flags when a conclusion no longer holds.
Use it for a board or client conversation: Pull a current, source-checked view of the analysis.
BenevolentAI's Use Cases
- Competitive positioning
- Trial-readout impact analysis
- Investor and board updates
- Consultancy research
